Idexx Laboratories has grown revenue 9.0% a year over three years and 8.4% a year over five, with earnings per share compounding at 15%. Revenue growth, 3-year annual rate: +9.0% (Diagnostics & Research median +8.4%). Revenue growth, 5-year rate: +8.4%, growth has picked up over the last three years. Earnings per share, 3-year rate: +15%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 18, FY2008 to FY2025, as filed.

IDXXIdexx Laboratories

Healthcare

$518.01-21% 1Y

$518.01

$504.5952 weeks$766.68

Is it growing?

Excellent

Growing: revenue growing +13% year on year, earnings up +18% year on year, and operating margin widening (+1.0 points).

3 good

Revenue trend+13% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +8% a year.

Earnings trend+18% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+1.0 points operating

Trailing-twelve-month operating margin, 32.0% now against 31.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsmiddle of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is IDXX growing?

Idexx Laboratories has grown revenue 9.0% a year over three years and 8.4% a year over five, with earnings per share compounding at 15%.

+9.0%

Revenue growth, 3-year annual rate · Diagnostics & Research median +8.4% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +8.4%
Revenue growth, 5-year rate · +9.0% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +15%
Earnings per share, 3-year rate · revenue +9.0% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed